Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.56 |
| ▸ | SUV39H2 | Q9H5I1 | 10/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14892233 | 0.87 | LMNA (0.53) | ALDH1A1LMNAMAPTSIRT6SUV39H2 | |
| SCHEMBL517279 | 0.86 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPTSIRT6MAPK1 | |
| SCHEMBL517280 | 0.86 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPTSIRT6MAPK1 | |
| SCHEMBL381140 | 0.85 | SIRT6 (0.56) | ALDH1A1LMNAMAPTSIRT6SUV39H2 | |
| SCHEMBL518051 | 0.84 | LMNA (0.43) | ALDH1A1LMNAMAPTSUV39H2DRD2 | |
| SCHEMBL29435443 | 0.83 | SUV39H2 (0.53) | SUV39H2CKS1BSKP1SKP2KDM4D | |
| SCHEMBL517615 | 0.83 | SUV39H2 (0.53) | SUV39H2CKS1BSKP1SKP2KDM4D | |
| SCHEMBL310101 | 0.82 | GPR119 (0.59) | ALDH1A1LMNAMAPTSIRT6 | |
| SCHEMBL12628007 | 0.82 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPTSIRT6MAPK1 | |
| SCHEMBL7235706 | 0.82 | HPGD (0.48) | ALDH1A1LMNAMAPTSUV39H2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390532-B2 | ALK protein regulator and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2025-08-19 | — | — | US | disclosed |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20220257776-A1 | ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-08-18 | — | — | US | disclosed |
| US-20220249482-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-08-11 | — | — | US | disclosed |
| EP-4029499-A1 | ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF | Shanghaitech University (CN) | 2022-07-20 | — | — | EP | disclosed |
| US-11253516-B2 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-02-22 | — | — | US | disclosed |
| EP-3725771-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | Shanghaitech University (CN) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019114770-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | 上海科技大学 | 2019-06-20 | — | — | WO | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | ALDH1A1 3281/4885LMNA 4230/4885MAPT 3181/4885 |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | ALDH1A1 214/4885LMNA 1889/4885MAPT 2815/4885 |
| US-12390532-B2 | ALK protein regulator and anti-tumor application thereof | ALK, MYC, ALKBH3 | ALDH1A1 1743/4885LMNA 3426/4885MAPT 4564/4885 |
| US-20220257776-A1 | ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF | ALK, MYC, ALKBH3 | ALDH1A1 1743/4885LMNA 3426/4885MAPT 4564/4885 |
| US-20220249482-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | FLT3, EGFR, ERBB2 | ALDH1A1 2330/4885LMNA 3636/4885MAPT 4112/4885 |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | ADRM1, VHL, MDM2 | ALDH1A1 1038/4885LMNA 986/4885MAPT 2785/4885 |
| US-11253516-B2 | N2,N4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer | FLT3, EGFR, ERBB2 | ALDH1A1 2330/4885LMNA 3636/4885MAPT 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.